WuXi STA Unveils New Parenteral Formulation Manufacturing Line


Will further boost CDMO’s injectable drug product platform

WuXi STA—a subsidiary of WuXi AppTec and a contract development and manufacturing organization (CDMO) serving the life sciences industry—has started operation of a new parenteral formulation manufacturing line at its drug product site in Jiangsu, China, a site featuring both drog product R&D and manufacturing.

It is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units. The expansion demonstrates the company’s commitment to enhancing its injectable drug product platform.

This new line features a fully automatic vial loading/unloading system and a built-in 15 m2 lyophilizer in a fully enclosed isolator. The filling line supports vials in a full range of sizes for solutions and lyophilized powder, while allowing rapid switches between modes for maximum filling flexibility and efficiency. The filling speed can reach 200 vials per minute, accelerating large-volume parental drug product production speed. This facility is also designed per global current good manufacturing practice (cGMP) standards.

"I am glad that our parenteral drug product capacity has been expanded to meet the growing demands,” comments Dr. Minzhang Chen, co-CEO of WuXi AppTec and CEO of WuXi STA. “… We strive to provide our global partners with flexible, fast, and cost-efficient solutions to accelerate new therapies to market for patients worldwide."

Read more about the CDMO's new manufacturing line here.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.